Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
2,550
datasets available to search
ShareScore release 0.7.1
Dataset results
2,550 results for “Glioblastoma”
The EGFRvIII Transcriptome in glioblastoma - public data repository
<p>Compiled dataset from a large omics EGFRvIII study.</p>
Activation level of 64 gene signatures in glioblastoma
<p>This repository includes the XGBoost models and the R scripts to infer the activation status of 64 gene signatures in GBM, as published in this manuscript:</p> <p><strong>Topographic mapping of the glioblastoma proteome reveals a triple axis model of intra-tumoral heterogeneity</strong><br> <em>Lam KHB, Leon AJ, Hui W, Lee SCE, Batruch I, Faust K, Koritzinsky M, Richer M, Djuric U, Diamandis P</em> <strong>(under review)</strong></p> <p>The models take as input proteomics (LFQ) of rna (TPM) expression data.</p> <p>Execute the following command to analyze the sample data:</p> <pre><code>Rscript predictXGB.R --data sample/sample_prot.rds \ --models data/list_xgb-gbm_64_signatures-prot-v01.RData \ --out_csv predictXGB_sample_rna.csv</code></pre>
Glioblastoma-astrocytes coculture data
<p>This dataset largely contains values pertaining to how migration from tumor spheroids in different coculture configurations with human astrocytes was measured. The data present relate to sphere size, the migration capacity or area %, and the adjusted migration distance or ad-distance of samples ranging over several days of measurements.</p> <p>Files are labeled to reflect data matching specific figure numbers. </p> <p>Most of the numerical data is derived from images that were initially batch processed in R using known packages and further processed manually in ImageJ and quantified. </p> <p>The Nanostring data represents gene expression results and needs to be further processed.</p>
Multi-omic integration of DNA methylation and gene expression data reveals molecular vulnerabilities in glioblastoma (processed data)
<p>Glioblastoma multiforme (GBM) is one of the most aggressive types of cancer and exhibits profound genetic and epigenetic heterogeneity, making the development of an effective treatment a major challenge. The recent incorporation of molecular features into the diagnosis of GBM patients has led to an improved categorisation into various tumour subtypes with different prognoses and disease management. In this work, we have exploited the benefits of genome-wide multi-omic approaches to identify potential molecular vulnerabilities existing in GBM patients. Integration of gene expression and DNA methylation data from both bulk GBM and patient-derived GBM stem cell lines has revealed the presence of major sources of GBM variability, pinpointing subtype-specific tumour vulnerabilities amenable to pharmacological interventions. In this sense, inhibition of the AP1, SMAD3 and RUNX1 / RUNX2 pathways, in combination or not with the chemotherapeutic agent temozolomide, led to the subtype-specific impairment of tumour growth, particularly in the context of the aggressive, mesenchymal-like subtype. These results emphasize the involvement of these molecular pathways in the development of GBM and have potential implications for the development of personalized therapeutic approaches.</p>
BrUOG 329 Onivyde & Metronomic Temozolomide in Recurrent Glioblastoma
ClinicalTrials.gov study NCT03119064. IPD Sharing: NO. Countries: 1. Publications: 1.
TRC105 for Recurrent Glioblastoma
ClinicalTrials.gov study NCT01778530. IPD Sharing: Not stated. Countries: 1. Publications: 3.
Vaccine Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
ClinicalTrials.gov study NCT00643097. IPD Sharing: Not stated. Countries: 1. Publications: 3.
Biological Therapy and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
ClinicalTrials.gov study NCT00052715. IPD Sharing: NO. Countries: 1. Publications: 1.
Neoadjuvant Chemoradiation for Resectable Glioblastoma
ClinicalTrials.gov study NCT04209790. IPD Sharing: NO. Countries: 1. Publications: 5.
A Study of PX-866 in Patients With Glioblastoma Multiforme at Time of First Relapse or Progression
ClinicalTrials.gov study NCT01259869. IPD Sharing: NO. Countries: 1. Publications: 1.
Mathematical Model-Adapted Radiation In Glioblastoma
ClinicalTrials.gov study NCT03557372. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Oral Pazopanib Plus Oral Topotecan Metronomic Antiangiogenic Therapy for Recurrent Glioblastoma Multiforme (A) Without Prior Bevacizumab Exposure and (B) After Failing Prior Bevacizumab
ClinicalTrials.gov study NCT01931098. IPD Sharing: NO. Countries: 1. Publications: 3.
Stereotactic Radiosurgery and Radiation Therapy in Treating Patients With Glioblastoma Multiforme
ClinicalTrials.gov study NCT00253448. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Everolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma
ClinicalTrials.gov study NCT00553150. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Oral Tarceva Study for Recurrent/Residual Glioblastoma Multiforme and Anaplastic Astrocytoma
ClinicalTrials.gov study NCT00301418. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Phase 0 Analysis of Ixazomib (MLN9708) in Patients With Glioblastoma
ClinicalTrials.gov study NCT02630030. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Study of Bevacizumab Plus Temodar and Tarceva in Patients With Glioblastoma or Gliosarcoma
ClinicalTrials.gov study NCT00525525. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Radiation Therapy (RT) and Temozolomide (TMZ) in Treating Patients With Newly Diagnosed Glioblastoma or Gliosarcoma
ClinicalTrials.gov study NCT00304031. IPD Sharing: Not stated. Countries: 2. Publications: 3.
An Investigational Immuno-therapy Study of Temozolomide Plus Radiation Therapy With Nivolumab or Placebo, for Newly Diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer)
ClinicalTrials.gov study NCT02667587. IPD Sharing: Not stated. Countries: 19. Publications: 2.
A Safety Study of Pharmacologic Ascorbate and Ferumoxytol in Addition to Standard of Care Chemoradiation in Glioblastoma
ClinicalTrials.gov study NCT04900792. IPD Sharing: YES. Countries: 1. Publications: 2.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.